NCT02078583

Brief Summary

Benzodiazepines is a commonly uesd sedative medication,there are many reports that Benzodiazepines is associated with delirium ,but using of analgesia reduces benzodiazepines requirements .The purpose of this study is to determine whether analgesia based sedation protocol reduces the incident of delirium.

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 28, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 5, 2014

Completed
4 months until next milestone

Study Start

First participant enrolled

July 1, 2014

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Last Updated

July 16, 2014

Status Verified

July 1, 2014

Enrollment Period

11 months

First QC Date

February 28, 2014

Last Update Submit

July 15, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • The incidence and duration of delirium in patients with different regimens

    1 day

Secondary Outcomes (9)

  • Mortality

    28 days

  • Ventilator-free days

    an expected average of 7 days

  • Mean days of mechanical ventilation

    an expected average of 7 days

  • Length of ICU stay

    an expected average of 7 days

  • Index of anesthesia depth monitoring

    From admission to ICU to weaning,about 7 days

  • +4 more secondary outcomes

Study Arms (3)

Remifentanil,midazolam

EXPERIMENTAL

Remifentanil 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02\~0.1mg/kg/h continuous intravenous pump for 7days or extubation

Drug: Remifentanil

Fentanyl,midazolam

EXPERIMENTAL

Fentanyl 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02\~0.1mg/kg/h continuous intravenous pump for 7days or extubation

Drug: Fentanyl

Normal saline

PLACEBO COMPARATOR

Normal saline1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02\~0.1mg/kg/h continuous intravenous pump for 7days or extubation

Drug: Normal saline

Interventions

Fentanyl,midazolam
Remifentanil,midazolam
Normal saline

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Signing a consent form
  • postoperative patient
  • Requirement for mechanical ventilation and anticipate time of mechanical ventilation more than 24 hours
  • Requirement for sedation
  • Age more than 18 and less than 85 years old

You may not qualify if:

  • Unstable blood circulation
  • Heart rate less than 50 beats per minute
  • II ° ~ III ° atrioventricular conduct block
  • Intracranial lesions 、neurosurgical intervention and mental disability inability to cooperate;
  • Receipt of antipsychotics 、hypnotic drugs before surgery ;
  • Alcohol abuse;
  • Liver failure class Child-Pugh C;
  • Acute Respiratory Distress Syndrome;
  • Acute or chronic renal failure;
  • Other severe diseases ,septic shock;
  • Receipt of neuromuscular blocking drug;
  • Pregnancy and nursing woman;
  • Allergy to investigational drug or other contraindication.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Delirium

Interventions

FentanylRemifentanilSaline Solution

Condition Hierarchy (Ancestors)

ConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPropionatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Central Study Contacts

Dan Liu, Resident physician

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 28, 2014

First Posted

March 5, 2014

Study Start

July 1, 2014

Primary Completion

June 1, 2015

Last Updated

July 16, 2014

Record last verified: 2014-07